SGRYSurgery Partners, Inc.

Price: $26.00 | Today's Change: +12.09%

---

What Happened

Surgery Partners, Inc. filed an 8-K with the SEC on November 9, 2026, covering Items 1.01, 7.01, and 9.01, disclosing its financial results for Q2 FY2026. Per the structured financial data extracted directly from the filing's official XBRL data, the company reported operating income of $173.6 million for the quarter, alongside a net loss of $40.2 million — translating to both basic and diluted earnings per share of -$0.32. The divergence between operating income and net loss signals that significant below-the-line charges — such as interest expense, amortization, or other non-operating items — are weighing heavily on the bottom line.

---

Why It Matters

For investors, the standout figure is the $173.6 million in operating income, which suggests that SGRY's core surgical facility operations are generating meaningful earnings power at the operating level. However, the $40.2 million net loss makes clear that the company's capital structure — which typically includes substantial debt servicing costs common in the ambulatory surgery center (ASC) rollup space — continues to consume a large portion of that operating cash generation. The stock's sharp move of +12.09% today implies the market is interpreting the operating-level performance as a positive surprise, or that other elements of the disclosure (potentially covered under Item 1.01, which typically relates to material agreements) are being received favorably. Investors should note the filing was made after the most recent trading session and is being reflected in today's price action.

Key points to track:

• The gap between $173.6M operating income and -$40.2M net loss implies roughly $213.8M in below-the-line charges for the quarter — the composition of these (interest, D&A, taxes, etc.) is critical context not fully detailed in the XBRL data provided.
• Item 1.01 of the 8-K pertains to entry into a material definitive agreement — the nature of any new contract or transaction disclosed under this item could have independent strategic significance.
• The EPS of -$0.32 is the reported GAAP figure; investors following this name often focus on adjusted metrics given the amortization-heavy nature of ASC acquisitions.

---

Analysis

The Q2 FY2026 results present a classic split-picture for Surgery Partners: strong operating leverage from its surgical facility network sitting above a capital structure that remains a drag on reported profitability. The $173.6 million operating income figure is a materially positive signal for a company whose growth model depends on the accretive addition of surgical facilities over time. The fact that shares are up over 12% today — trading well above the $21.00 price target from our initiating coverage published September 22, 2026 — suggests the market may be re-rating the business based on this operating performance, or potentially on news disclosed under Item 1.01 of this same filing.

What to watch next:

• Management commentary on the drivers of below-the-line charges and any debt refinancing activity.
• Details of the material agreement disclosed under Item 1.01 — this could range from a new partnership, acquisition financing, or credit facility amendment.
• Whether the operating income trajectory is sustainable across subsequent quarters, particularly as integration costs from any recent acquisitions normalize.
• Volume and case mix data, which are not available in the XBRL structured facts but are key to assessing same-facility growth.

The divergence between GAAP net loss and robust operating income is a known feature of the ASC rollup model, and the market's reaction today suggests investors may be increasingly comfortable looking through the GAAP loss to the underlying operational performance.

---

Disclaimer

This report is a news and informational analysis of a public SEC filing and is provided for informational purposes only. It does not constitute investment advice, a solicitation, or an offer to buy or sell any security. The structured financial figures cited are sourced exclusively from the official XBRL data attached to the referenced SEC filing. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decision.

Existing Coverage

StockWatch has full coverage on SGRY, published 2026-09-22. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-09. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1638833/000110465926124236/tm2629312d1_8k.htm